Datapoint: FDA Approves Lexicon’s Heart Failure Drug

The FDA on May 26 approved Lexicon Pharmaceuticals’ Inpefa (sotagliflozin) to reduce the risk of heart failure in select patient populations, including adults with Type 2 diabetes and chronic kidney disease. The once-daily pill will be the first SGLT1/SGLT2 inhibitor in the market basket, and is expected to launch by the end of June. Among the most advantaged therapies for chronic heart failure are AstraZeneca’s Farxiga, which is placed on the preferred tier for 49.6% of all insured lives under the pharmacy benefit, and Boehringer Ingelheim and Eli Lilly’s Jardiance, which is preferred for 65.11% of lives.

SOURCE: MMIT Analytics, as of 5/31/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 24

Datapoint: FDA Approves Alvotech and Teva’s Stelara Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 23

Datapoint: Elevance to Take On Primary Care Expansion

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 18

Datapoint: FDA Delays New Leqembi Launch

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today